Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Draft Nat'l Medical Expenditure Optimization Plan Announced
September 8, 2008
- Thalidomide Safety Control Criteria Discussed by Study Group
September 8, 2008
- TOPICS／Society to Prevent Uterocervical Cancer Inaugurated
September 8, 2008
- CDFS Committee Recommends Conditional Approval of Thalidomide
September 8, 2008
- Seven APIs Recommended for Switching to OTC Status
September 8, 2008
- 16 Products (11 APIs) Recommended for NHI Price Listing
September 8, 2008
- Use of CyberKnife II to Treat Tumors in Trunk of the Body Approved: Accuray
September 8, 2008
- BUSINESS NEWS IN BRIEF
September 8, 2008
- Terumo's DuraHeart Implanted in 1st Patient in US
September 8, 2008
- Yamato Expects Profits from Generics Delivery Service in 3 Years
September 8, 2008
- BD Enters Market for Cytodiagnostic Systems for Cervical Cancer
September 8, 2008
- Sanwa Kagaku Licenses SK-0403 to ChoongWae in South Korea
September 8, 2008
- Vascular Embolization Set for AVM Recommended for Approval
September 8, 2008
- Shionogi to Directly Enter US Market by Acquiring Sciele Pharma
September 8, 2008
- R&D NEWS IN BRIEF
September 8, 2008
- Astellas Aims at Top Market Share in Japan
September 8, 2008
- 4 Healthcare Clusters to Focus on 4 Fields
September 8, 2008
- Prevent Recurrence of Stroke: Prof. Hasegawa
September 8, 2008
- No Evidence for Giving Priority to Iressa: CDFS
September 1, 2008
- Tokai Univ. to Settle Prices of Individual Drugs within Sept.
September 1, 2008
ページ
Strategic Talent Acquisition in the Japanese Life Sciences Sector: Your Market Intelligence Briefing
Focus: How to Get the Talent You Need in a Tough MarketThe Japanese life sciences sector presents a challenging landscape for global companies. To succeed, you must move beyond reactive hiring and adopt a truly strategic talent acquisition model. Our…
Japan’s FY2026 drug price revision, officially announced on March 5, has landed poorly with the pharmaceutical industry — and the…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…